Evidence map›Paper›PMID 41383739›Full record

ArticleFrontiers in microbiology2025

Mesenchymal stem cells alleviate pulmonary fibrosis and gut microbiota dysbiosis in systemic sclerosis.

Biao Ni, Yufang Gong, Bin Li, Lijie Qiu, Kang He, Jintao Guo, Hongkun Fang, Mingjie Gao, Min Chen, Cuie Wei and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Biao Ni *Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Yufang Gong *Department of Rheumatology, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Bin Li *Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Lijie Qiu *Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Kang HeDepartment of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Jintao GuoDepartment of Scientific Research Management, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Hongkun FangDepartment of Scientific Research Management, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Mingjie GaoDepartment of Scientific Research Management, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Min ChenDepartment of Scientific Research Management, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Cuie WeiDepartment of Rheumatology, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Weice SunDepartment of Vascular Surgery, Weifang Hospital of Traditional Chinese Medicine, Weifang, Shandong, China.
Bin LiuWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Ming LiDepartment of Rheumatology, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Shaoqiang WangDepartment of Scientific Research Management, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Lina XuDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Mesenchymal stem cells (MSCs) have shown the potential to alleviate systemic sclerosis (SSc) tissue fibrosis. However, our knowledge of the effects of MSCs on gut microbiota remains limited. Methods: In this study, we employed a bleomycin induced SSc model to investigate the effects of MSCs on pulmonary fibrosis and gut microbiota in SSc using transcriptomic, microbial metagenomic, and metabolomic analyses. Results: Our results indicated that MSCs treatment alleviated lung injury in SSc mice. Transcriptomic analysis suggested that the therapeutic effects of MSCs were primarily associated with fatty acid metabolism, PPAR signaling pathway, and AMPK signaling pathway. Furthermore, MSCs restored the relative abundance of microbial taxa, including Discussion: Collectively, our findings indicate that MSCs may alleviate SSc pulmonary fibrosis by reshaping the gut microbiota, thereby offering novel scientific insights for the investigation of clinical treatment targets for SSc.

Indexed as

gut microbiotamesenchymal stem cellsmicrobial metabolitespulmonary fibrosissystemic sclerosis

Identifiers

PMID41383739
PMCPMC12693401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.